← Back to Search

Phosphodiesterase-4 (PDE-4) Inhibitor

Apremilast for Alopecia Areata

N/A
Waitlist Available
Led By Emma Guttman, MD, PhD
Research Sponsored by Icahn School of Medicine at Mount Sinai
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline and week 4, 8, 12, 16, 20, 24
Awards & highlights

Study Summary

Alopecia areata (AA) is a medical condition, in which the hair falls out in patches. The hair can fall out on the scalp or elsewhere on the face and body. Alopecia areata is an autoimmune skin disease, which means that the immune system is recognizing the hair follicles as foreign and attacking them, causing round patches of hair loss. It can progress to total scalp hair loss (alopecia totalis) or complete body hair loss (alopecia universalis). The scalp is the most commonly affected area, but the beard or any hair-bearing site can be affected alone or together with the scalp. Alopecia areata occurs in males and females of all ages, and is a highly unpredictable condition that tends to recur. Alopecia areata can cause significant distress to both patients and their families. In this study, the aim to assess the effects of a new treatment called apremilast in patients with alopecia areata. A total of 30 patients will be included in the study, which will run for a total of 52 weeks.

Eligible Conditions
  • Alopecia Areata

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline and week 4, 8, 12, 16, 20, 24
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline and week 4, 8, 12, 16, 20, 24 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Number of Patients With SALT50
Secondary outcome measures
Mean Change in SALT Score
Phase 2: AA-QoL
Phase 2: Change in AASIS
+2 more

Trial Design

2Treatment groups
Active Control
Placebo Group
Group I: ApremilastActive Control1 Intervention
Apremilast 30mg twice daily
Group II: PlaceboPlacebo Group1 Intervention
Placebo pills twice daily

Find a Location

Who is running the clinical trial?

Icahn School of Medicine at Mount SinaiLead Sponsor
861 Previous Clinical Trials
525,246 Total Patients Enrolled
6 Trials studying Alopecia Areata
201 Patients Enrolled for Alopecia Areata
Emma Guttman, MD, PhDPrincipal InvestigatorISMMS
7 Previous Clinical Trials
387 Total Patients Enrolled
2 Trials studying Alopecia Areata
62 Patients Enrolled for Alopecia Areata

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~3 spots leftby Apr 2025